Etanercept treatment in corticosteroid-dependent myasthenia gravis

J. Rowin, M. N. Meriggioli, E. Tüzün, S. Leurgans, P. Christadoss

Research output: Contribution to journalArticle

69 Scopus citations


The authors report a prospective pilot trial of etanercept in corticosteroid-dependent autoimmune myasthenia gravis. Eleven patients were enrolled, with eight completing the 6-month trial. Two patients were withdrawn owing to disease worsening, and one patient was withdrawn because of an erythematous skin rash. Six of the eight patients who completed the trial improved, based on quantitative measures of muscle strength and lowering of corticosteroid requirement.

Original languageEnglish (US)
Pages (from-to)2390-2392
Number of pages3
Issue number12
StatePublished - Dec 28 2004


ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Rowin, J., Meriggioli, M. N., Tüzün, E., Leurgans, S., & Christadoss, P. (2004). Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology, 63(12), 2390-2392.